La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Q-linea Bilan de santé

Santé financière contrôle des critères 3/6

Q-linea possède un total de capitaux propres de SEK68.1M et une dette totale de SEK41.5M, ce qui porte son ratio d'endettement à 60.9%. Son actif total et son passif total sont SEK159.0M et de SEK90.9M.

Informations clés

60.9%

Ratio d'endettement

SEK 41.50m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	SEK 20.86m
Fonds propres	SEK 68.11m
Total du passif	SEK 90.87m
Total des actifs	SEK 158.97m

Mises à jour récentes de la santé financière

Recent updates

Here's Why Q-linea (STO:QLINEA) Must Use Its Cash Wisely

Dec 31

Will Q-linea (STO:QLINEA) Spend Its Cash Wisely?

May 07

Q-linea (STO:QLINEA) Is In A Good Position To Deliver On Growth Plans

Jan 11

We're Hopeful That Q-linea (STO:QLINEA) Will Use Its Cash Wisely

Feb 17

Do Institutions Own Q-linea AB (publ) (STO:QLINEA) Shares?

Dec 26

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de QLINEA ( SEK97.9M ) dépassent ses passifs à court terme ( SEK82.2M ).

Passif à long terme: Les actifs à court terme de QLINEA ( SEK97.9M ) dépassent ses passifs à long terme ( SEK8.7M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de QLINEA ( 30.3% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de QLINEA est passé de 0.2% à 60.9% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: QLINEA dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: QLINEA dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 11.3 % chaque année

Q-linea Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

Here's Why Q-linea (STO:QLINEA) Must Use Its Cash Wisely

Will Q-linea (STO:QLINEA) Spend Its Cash Wisely?

Q-linea (STO:QLINEA) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Q-linea (STO:QLINEA) Will Use Its Cash Wisely

Recent updates

Consensus revenue estimates fall by 42%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Q-linea AB (publ) to Report Q1, 2025 Results on May 03, 2025

Q-linea AB (publ) Approves the Election of Jonas Jarvius as Members of the Board of Directors

Consensus revenue estimates increase by 49%

First quarter 2024 earnings released: kr0.48 loss per share (vs kr2.10 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates increase by 24%, EPS downgraded

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings: EPS and revenues miss analyst expectations

Q-Linea AB Appoints Anders Ljunggren as Managing Director, Effective 1 March 2024

Q-linea AB (publ) Announces CEO Changes

Q-linea AB (publ) to Report First Half, 2024 Results on Jul 11, 2024

Q-linea AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Here's Why Q-linea (STO:QLINEA) Must Use Its Cash Wisely

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 27%

Price target decreased by 13% to kr10.00

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Q-Linea AB (Publ) Announces Jonas Jarvius to Step Down as CEO Before Summer 2024

Q-linea AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 262.885275 million.

New major risk - Share price stability

Consensus revenue estimates decrease by 40%, EPS upgraded

Q-linea AB (publ) Completes its 510(k) Application for US Market Approval

Second quarter 2023 earnings released: kr2.23 loss per share (vs kr2.53 loss in 2Q 2022)

Q-linea AB (publ) Announces First Patient Enrolls in Lifetimes

Consensus revenue estimates increase by 40%, EPS downgraded

Insufficient new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

CFO & Investor Relations Officer recently bought kr143k worth of stock

Full year 2022 earnings released: kr9.20 loss per share (vs kr8.19 loss in FY 2021)

Q-linea AB (publ) Announces CFO Changes, Effective May 1, 2023

Q-linea AB (publ) Prepare to Start Additional Testing for US 510(K) Application

Q-Linea Participates in Comparative Rapid AST Study

VP & Research Director recently bought kr241k worth of stock

Consensus revenue estimates fall by 21%

Q-linea AB (publ) to Report Q1, 2023 Results on May 04, 2023

Third quarter 2022 earnings released: kr2.03 loss per share (vs kr1.68 loss in 3Q 2021)

Consensus revenue estimates fall by 34%

Second quarter 2022 earnings released: kr2.53 loss per share (vs kr2.47 loss in 2Q 2021)

Consensus revenue estimates fall by 82%

Will Q-linea (STO:QLINEA) Spend Its Cash Wisely?

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Price target decreased to kr165

Q-linea AB (publ) Announces Marcus Storch Not Available for Re-Election as Member of Board of Directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

CEO & President recently bought kr480k worth of stock

Insufficient new directors

Now 22% undervalued after recent price drop

Price target decreased to kr165

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS and revenues miss analyst expectations

Q-linea (STO:QLINEA) Is In A Good Position To Deliver On Growth Plans

Forecast to breakeven in 2023

Third quarter 2021 earnings released: kr1.68 loss per share (vs kr1.80 loss in 3Q 2020)

Forecast to breakeven in 2023

Second quarter 2021 earnings released: kr2.47 loss per share (vs kr2.37 loss in 2Q 2020)

CEO & President recently sold kr14m worth of stock

Q-linea AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 301.4 million.

Q-linea AB (publ) Initiates US 510(k) Clinical Study for ASTar

Consensus forecasts updated

First quarter 2021 earnings released: kr2.34 loss per share (vs kr2.44 loss in 1Q 2020)

Full year 2020 earnings released: kr8.64 loss per share (vs kr7.74 loss in FY 2019)

Price target increased to kr185

Q-linea AB (publ) Receives First Order on ASTar

Full year 2020 earnings released: kr8.64 loss per share (vs kr7.74 loss in FY 2019)

Revenue beats expectations

We're Hopeful That Q-linea (STO:QLINEA) Will Use Its Cash Wisely

New 90-day low: kr150